Table 4.

Anti-CS antibody seropositivity rates and geometric mean concentrations (GMC) one month post-dose 3 (adapted^* according to Protocol immunogenicity cohort).

			≥ 0.5 EU/ml			GMC
Group	Timing	N	n	%	(95% CI)	value	(95% CI)
R1	Screening	141	91	64.5	(56.0; 72.4)	0.7	(0.6; 0.9)
	Post 3	141	141	100	(97.4; 100)	142.2	(116.4; 173.7)
R2	Screening	124	87	70.2	(61.3; 78.0)	0.8	(0.7; 0.9)
	Post 3	123	123	100	(97.0; 100)	188.5	(156.5; 227.0)
R3	Screening	137	80	58.4	(49.7; 66.7)	0.6	(0.6; 0.8)
	Post 3	136	135	99.3	(96.0; 100)	205.5	(167.3; 252.5)
C1	Screening	136	84	61.8	(53.0; 70.0)	0.6	(0.6; 0.7)
	Post 3	135	16	11.9	(6.9; 18.5)	0.3	(0.3; 0.3)
C2	Screening	118	75	63.6	(54.2; 72.2)	0.7	(0.6; 0.8)
	Post 3	118	12	10.2	(5.4; 17.1)	0.3	(0.3; 0.4)

Group R1 received RTS,S/AS01 + (DTaP/Hib + tOPV + PHiD-CV), and HRV 2 weeks later.

Group R2 received RTS,S/AS01 + (DTaP/Hib + tOPV + HRV), and PHiD-CV 2 weeks later.

Group R3 received RTS,S/AS01 + (DTaP/Hib + tOPV), and (PHiD-CV + HRV) 2 weeks later.

Group C1 received HBV + (DTaP/Hib + tOPV + PHiD-CV), and HRV 2 weeks later.

Group C2 received HBV + (DTaP/Hib + tOPV + HRV), and PHiD-CV 2 weeks later.

N = number of participants with available results, n/% = number/percentage of participants with concentration ≥ specified value, CS = circumsporozoite protein, 95% CI = 95% confidence interval, Screening = Pre-vaccination, Post 3 = one month post-dose 3, DTaP/Hib = diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type-b-conjugate vaccine, tOPV = trivalent oral poliovirus vaccine, PHiD-CV = 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine, HRV = human rotavirus vaccine.

^*The adapted cohort is the according-to-protocol cohort at each individual time point.